Zai Lab to Participate in 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
- Conference Participation: Zai Lab will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:00 p.m. PST, showcasing its innovative research in oncology, immunology, and other fields, aiming to enhance its visibility in the biopharmaceutical industry.
- Live Webcast: The event will be streamed live on Zai Lab's Investor Relations page, allowing global investors to stay updated on the company's latest developments, which is expected to bolster investor confidence.
- Replay Availability: An archived replay of the presentation will be available for up to 30 days post-event, ensuring that investors who cannot attend live can still access critical information, thereby enhancing transparency.
- Company Background: Zai Lab is an innovative biopharmaceutical company based in China and the U.S., focused on developing products that address significant unmet medical needs, and this conference will further emphasize its strategic positioning in the global biopharmaceutical market.
Trade with 70% Backtested Accuracy
Analyst Views on 09688
About the author
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
M Stanley Predicts WUXI BIO (02269.HK) Share Price Increase in Next 45 Days, Raises Target Price to $50
Morgan Stanley's Prediction: Morgan Stanley forecasts a 70-80% probability that WUXI BIO's share price will rise in the next 45 days, following a positive profit alert and management guidance indicating accelerated growth in FY2026.
Earnings Forecast Adjustment: The broker has raised its earnings forecasts for WUXI BIO from 2026 to 2030 by 4-10% and increased the target price from $45 to $50, maintaining an Overweight rating.
Recent Stock Performance: WUXI BIO's stock opened 2.71% higher and reached a peak of $44, marking a two-year high, with a trading volume of approximately 24.89 million shares.
Research Services Momentum: The company is experiencing strong momentum in research services, which is expected to enhance profitability through IP-related revenue and recent out-licensing deals with Vertex and ZAI LAB.
Zai Lab to Participate in 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
- Conference Participation: Zai Lab will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:00 p.m. PST, showcasing its innovative research in oncology, immunology, and other fields, aiming to enhance its visibility in the biopharmaceutical industry.
- Live Webcast: The event will be streamed live on Zai Lab's Investor Relations page, allowing global investors to stay updated on the company's latest developments, which is expected to bolster investor confidence.
- Replay Availability: An archived replay of the presentation will be available for up to 30 days post-event, ensuring that investors who cannot attend live can still access critical information, thereby enhancing transparency.
- Company Background: Zai Lab is an innovative biopharmaceutical company based in China and the U.S., focused on developing products that address significant unmet medical needs, and this conference will further emphasize its strategic positioning in the global biopharmaceutical market.
Zai Lab Receives NMPA Approval for COBENFY to Treat Schizophrenia
- Innovative Therapy Approval: Zai Lab's COBENFY (xanomeline and trospium chloride) has received approval from China's NMPA, becoming the first new mechanism schizophrenia treatment in over 70 years, marking a significant breakthrough in schizophrenia care.
- Addressing Patient Needs: With approximately 8 million adults in China suffering from schizophrenia and existing treatments offering limited efficacy, COBENFY selectively activates M1 and M4 receptors to provide broader symptom improvement, which is expected to significantly enhance patients' quality of life.
- Clinical Research Support: The NMPA approval is backed by results from a Phase 1 pharmacokinetics study and Phase 3 clinical trials in China, demonstrating COBENFY's effectiveness in improving positive, negative, and cognitive symptoms while avoiding the side effects commonly associated with traditional antipsychotics.
- Enhanced Industry Influence: The inclusion of COBENFY in the China Schizophrenia Prevention and Treatment Guidelines (2025 Edition) not only elevates Zai Lab's standing in the mental health sector but also lays a foundation for future market expansion.
<Research>UBS Identifies Chinese Stocks with Greatest Potential for FY26 Earnings Growth (Table)
UBS China Market Strategy Report: UBS has released a report highlighting Buy-rated Chinese stocks with significant potential for earnings growth by FY26, focusing on Hong Kong-listed and ADR-listed companies.
Highlighted Stocks: The report includes stocks such as INNOCARE, CARSGEN-B, ZAI LAB, AKESO, and CANSINOBIO, along with their recent performance and short selling data.
Short Selling Data: The report provides short selling figures for the listed stocks, indicating varying levels of short interest, with ZAI LAB and AKESO showing higher short selling ratios.
Related Market Insights: Additional context is provided by Soochow Securities, which lists the top 10 Hong Kong stocks with the highest net buys and sells by southbound funds in the previous week.
Citi Lowers ZAI LAB (09688.HK) Price Target to US$58 Following Disappointing 3Q Revenue Results
Revenue Performance: ZAI LAB reported a total revenue of approximately US$116 million for 3Q25, which fell short of expectations by 16% and 22% according to Citi Research and the market, respectively.
Revised Guidance: The company significantly lowered its 2025 revenue guidance from US$560-590 million to at least US$460 million and abandoned its goal of achieving operational expense balance this year.
Market Reaction: Following the revenue miss and guidance cut, Citi Research adjusted its target price for ZAI LAB from US$69 to US$58, maintaining a Buy/High Risk rating.
Short Selling Activity: ZAI LAB experienced short selling of $134.05 million, with a short selling ratio of 19.425%.
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
M Stanley Predicts WUXI BIO (02269.HK) Share Price Increase in Next 45 Days, Raises Target Price to $50
Morgan Stanley's Prediction: Morgan Stanley forecasts a 70-80% probability that WUXI BIO's share price will rise in the next 45 days, following a positive profit alert and management guidance indicating accelerated growth in FY2026.
Earnings Forecast Adjustment: The broker has raised its earnings forecasts for WUXI BIO from 2026 to 2030 by 4-10% and increased the target price from $45 to $50, maintaining an Overweight rating.
Recent Stock Performance: WUXI BIO's stock opened 2.71% higher and reached a peak of $44, marking a two-year high, with a trading volume of approximately 24.89 million shares.
Research Services Momentum: The company is experiencing strong momentum in research services, which is expected to enhance profitability through IP-related revenue and recent out-licensing deals with Vertex and ZAI LAB.
Zai Lab to Participate in 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
- Conference Participation: Zai Lab will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 3:00 p.m. PST, showcasing its innovative research in oncology, immunology, and other fields, aiming to enhance its visibility in the biopharmaceutical industry.
- Live Webcast: The event will be streamed live on Zai Lab's Investor Relations page, allowing global investors to stay updated on the company's latest developments, which is expected to bolster investor confidence.
- Replay Availability: An archived replay of the presentation will be available for up to 30 days post-event, ensuring that investors who cannot attend live can still access critical information, thereby enhancing transparency.
- Company Background: Zai Lab is an innovative biopharmaceutical company based in China and the U.S., focused on developing products that address significant unmet medical needs, and this conference will further emphasize its strategic positioning in the global biopharmaceutical market.
Zai Lab Receives NMPA Approval for COBENFY to Treat Schizophrenia
- Innovative Therapy Approval: Zai Lab's COBENFY (xanomeline and trospium chloride) has received approval from China's NMPA, becoming the first new mechanism schizophrenia treatment in over 70 years, marking a significant breakthrough in schizophrenia care.
- Addressing Patient Needs: With approximately 8 million adults in China suffering from schizophrenia and existing treatments offering limited efficacy, COBENFY selectively activates M1 and M4 receptors to provide broader symptom improvement, which is expected to significantly enhance patients' quality of life.
- Clinical Research Support: The NMPA approval is backed by results from a Phase 1 pharmacokinetics study and Phase 3 clinical trials in China, demonstrating COBENFY's effectiveness in improving positive, negative, and cognitive symptoms while avoiding the side effects commonly associated with traditional antipsychotics.
- Enhanced Industry Influence: The inclusion of COBENFY in the China Schizophrenia Prevention and Treatment Guidelines (2025 Edition) not only elevates Zai Lab's standing in the mental health sector but also lays a foundation for future market expansion.
<Research>UBS Identifies Chinese Stocks with Greatest Potential for FY26 Earnings Growth (Table)
UBS China Market Strategy Report: UBS has released a report highlighting Buy-rated Chinese stocks with significant potential for earnings growth by FY26, focusing on Hong Kong-listed and ADR-listed companies.
Highlighted Stocks: The report includes stocks such as INNOCARE, CARSGEN-B, ZAI LAB, AKESO, and CANSINOBIO, along with their recent performance and short selling data.
Short Selling Data: The report provides short selling figures for the listed stocks, indicating varying levels of short interest, with ZAI LAB and AKESO showing higher short selling ratios.
Related Market Insights: Additional context is provided by Soochow Securities, which lists the top 10 Hong Kong stocks with the highest net buys and sells by southbound funds in the previous week.
Citi Lowers ZAI LAB (09688.HK) Price Target to US$58 Following Disappointing 3Q Revenue Results
Revenue Performance: ZAI LAB reported a total revenue of approximately US$116 million for 3Q25, which fell short of expectations by 16% and 22% according to Citi Research and the market, respectively.
Revised Guidance: The company significantly lowered its 2025 revenue guidance from US$560-590 million to at least US$460 million and abandoned its goal of achieving operational expense balance this year.
Market Reaction: Following the revenue miss and guidance cut, Citi Research adjusted its target price for ZAI LAB from US$69 to US$58, maintaining a Buy/High Risk rating.
Short Selling Activity: ZAI LAB experienced short selling of $134.05 million, with a short selling ratio of 19.425%.
